Agenus Inc. (NASDAQ:AGEN) announced a global license, development and commercialization agreement with Incyte Corp. Friday morning. Incyte will make upfront payments to Agenus totaling $25 million and will also invest $35 million in the company, through the purchase of newly issued shares of Agenus. On Tuesday shares of Agenus Inc. (NASDAQ:AGEN) closed at $5.70. Company’s sales growth for last 5 years was 2.10%.
On January 6, Yingli Green Energy Holding Co. Ltd. (NYSE:YGE), a leading solar panel manufacturer in the world, announced that the Company gone beyond its targets to reduce greenhouse gas (GHG) emissions by the end of 2013 as part of its membership commitments in the World Wide Fun for Nature (WWF) Climate Savers program, according to internal inspections report. Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) in last trading activity moved down -2.01% to close at $1.95. Company weekly performance is -10.55% while its quarterly performance stands at -21.05%. Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) is -73.36% away from its 52 week high.
Synaptics, Inc (NASDAQ:SYNA) SVP Scott Deutsch sold 1,162 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $69.67, for a total value of $80,956.54. Following the completion of the transaction, the senior vice president now directly owns 11,602 shares in the company, valued at approximately $808,311. On last trading day Synaptics Inc. (NASDAQ:SYNA) moved up 0.83% to close at $60.88. Its volatility for the week is 3.17% while volatility for the month is 3.54%. SYNA’s sales growth for past 5 years was 14.90% and its EPS growth for past 5 years was -1.40%. Synaptics Inc. (NASDAQ:SYNA) monthly performance is -9.24%.
On January 9, Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc. (NASDAQ:ONTY), Surface Oncology and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner. Oncothyreon Inc (NASDAQ:ONTY) has 4.20% insider ownership while its institutional ownership stands at 58.30%. In last trading activity company’s stock closed at $1.61.
On January 8, According to news reporting originating from Washington, D.C., by VerticalNews journalists, a U.S. Securities and Exchange Commission(SEC) filing by Entropic Communications Inc. (NASDAQ:ENTR) was posted on December 29, 2014. On last trading day Entropic Communications, Inc. (NASDAQ:ENTR) moved up 0.83% to close at $2.44. Its volatility for the week is 5.58% while volatility for the month is 6.00%. ENTR’s sales growth for past 5 years was 12.20% and its EPS growth for past 5 years was 18.30%. Entropic Communications, Inc. (NASDAQ:ENTR) monthly performance is -2.40%.